Dr. Campbell joined Axial Therapeutics in 2017 and became CEO in 2021. He brings nearly 30 years of experience leading and building teams that have strong track records of discovering and developing novel therapeutics for the patients who need them. Since starting his career as a medicinal chemist at Boehringer Ingelheim, Dr. Campbell has since held various leadership roles at biopharmaceutical and chemical manufacturing companies, including Corden Pharma, Surface Logix and Insmed. He played an integral role in the discovery and development of seven clinical-stage drug candidates, including AB-2004 for managing irritability associated with autism and the Rho kinase inhibitor belumosudil (Rezurock™). Dr. Campbell has been a co-inventor on 25 issued patents. He received his Ph.D. in Chemistry from the Queen’s University and completed post-doctoral research at Duke University.